Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of different dose regimens of CD5789 (tazarotene gel) in acne vulgaris
2010-022211-19Phase 2Completed
- Sponsor
- Galderma
- Start
- Sep 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of tazarotene in acne vulgaris (4 arms), sponsored by Galderma. Primary endpoints: Total acne lesion count at end of treatment and Percent reduction in total acne lesion count at end of treatment. Started Sep 2010; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on 2010-022211-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022211-19.